Stem Cells News and Research

RSS

Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

Six young scientists to receive 2012 Klerman and Freedman Awards

Six young scientists will be recognized with the Annual Klerman and Freedman Awards by the Brain & Behavior Research Foundation on Friday July 27, 2012 at Le Parker Meriden Hotel in New York City on Friday, July 27.

18 Jul 2012

Nanofiber scaffolds regenerate protein components in cartilage repair

Johns Hopkins tissue engineers have used tiny, artificial fiber scaffolds thousands of times smaller than a human hair to help coax stem cells into developing into cartilage, the shock-absorbing lining of elbows and knees that often wears thin from injury or age. Reporting online June 4 in the Proceedings of the National Academy of Sciences, investigators produce an important component of cartilage in both laboratory and animal models.

18 Jul 2012

Three outstanding young scientists named July 2012 Damon Runyon-Sohn Fellows

The Damon Runyon Cancer Research Foundation and the Sohn Conference Foundation have named three outstanding young scientists as the first-ever Damon Runyon-Sohn Pediatric Cancer Research Fellows, committing more than half a million dollars to help address a critical shortage of funding for pediatric cancer research.

18 Jul 2012

Jade, BioTime sign exclusive sublicense and supply agreement for HyStem

BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement and a supply agreement with Jade Therapeutics, LLC, a developer of an ophthalmological therapeutic sustained-release drug delivery platform.

18 Jul 2012

Promising path to Parkinson’s disease treatment

Using adult stem cells, Johns Hopkins researchers and a consortium of colleagues nationwide say they have generated the type of human neuron specifically damaged by Parkinson’s disease (PD) and used various drugs to stop the damage.

17 Jul 2012

New Alzheimer's model derived from skin cells of patients may prove to be more accurate

Researchers at the Alzheimer's Association International Conference 2012 (AAIC 2012) today reported the creation of a new model of Alzheimer's derived from the skin cells of people with the disease that were reprogramed into Alzheimer's brain cells.

17 Jul 2012

Relationship between two biological risk factors for schizophrenia

Johns Hopkins researchers say they have discovered a cause-and-effect relationship between two well-established biological risk factors for schizophrenia previously believed to be independent of one another.

17 Jul 2012

Activating NOTCH and AKT gene may trigger cholangiocarcinoma

A rare type of cancer thought to derive from cells in the bile ducts of the liver may actually develop when one type of liver cell morphs into a totally different type, a process scientists used to consider all but impossible. UCSF researchers triggered this kind of cellular transformation-and caused tumors to form in mice-by activating just two genes.

17 Jul 2012

Life Technologies acquires Navigenics

Life Technologies Corporation today announced the acquisition of Navigenics, Inc. This acquisition represents Life Technologies' first step in executing against a strategy to build out its molecular diagnostics business through internal development, partnerships and select acquisitions.

17 Jul 2012

Scientists discover new way to convert cord blood cells into iNC

For more than 20 years, doctors have been using cells from blood that remains in the placenta and umbilical cord after childbirth to treat a variety of illnesses, from cancer and immune disorders to blood and metabolic diseases.

17 Jul 2012

Scientists develop first cell-based model of Alzheimer's disease

A team of scientists at The New York Stem Cell Foundation (NYSCF) Laboratory led by Scott Noggle, PhD, NYSCF-Charles Evans Senior Research Fellow for Alzheimer's Disease, has developed the first cell-based model of Alzheimer's disease (AD) by reprogramming skin cells of Alzheimer's patients to become brain cells that are affected in Alzheimer's.

17 Jul 2012

InvivoSciences, WUSTL to construct artificial tissue models for heart failure

The National Institutes of Health has awarded more than $2 million to a team of scientists from Washington University in St. Louis and InvivoSciences, a biotechnology startup with WUSTL roots, to construct artificial tissue models that will allow the rapid testing of new drugs for heart failure.

17 Jul 2012

Ajuba protein plays a central role in regulating function of heart stem cells

It is not unusual for babies to be born with congenital heart defects. This is because the development of the heart in the embryo is a process which is not only extremely complex, but also error-prone. Scientists from the Max Planck Institute for Heart and Lung Research in Bad Nauheim have now identified a key molecule that plays a central role in regulating the function of stem cells in the heart.

14 Jul 2012

ACT treats fourth patient in U.S. clinical trial for Stargardt's Macular Dystrophy

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced treatment of the fourth patient, the first in the second patient cohort, in its U.S. clinical trial for Stargardt's Macular Dystrophy (SMD).

13 Jul 2012

Scientists isolate new type of energy-burning fat cell

Scientists at Dana-Farber Cancer Institute have isolated a new type of energy-burning fat cell in adult humans which they say may have therapeutic potential for treating obesity.

13 Jul 2012

OncoMed commences dosing in OMP-54F28 Phase I clinical trial for advanced solid tumor cancers

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells, or tumor-initiating cells, today announced that patient dosing has begun in a Phase I clinical trial of OMP-54F28 in patients with advanced solid tumor cancers.

13 Jul 2012

Eisai, Verastem partner for next-generation of small molecule Wnt inhibitors

Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced a research collaboration with Eisai for the next-generation of small molecule Wnt inhibitors.

12 Jul 2012

Maraviroc reduces incidence of GvHD in blood cancer patients after bone marrow transplantation

An HIV drug that redirects immune cell traffic significantly reduces the incidence of a dangerous complication that often follows bone marrow transplants for blood cancer patients, according to research from the Perelman School of Medicine at the University of Pennsylvania that will be published today in the New England Journal of Medicine.

12 Jul 2012

Manipulating retinal recipient microenvironment impacts photoreceptor cell transplantation

A research team in the United Kingdom has found that insulin-like growth factor (IGF1) impacts cell transplantation of photoreceptor precursors by manipulating the retinal recipient microenvironment, enabling better migration and integration of the cells into the adult mouse retina.

12 Jul 2012

Eschar-derived cells may be used for tissue engineering

A research team in the Netherlands has found that cells from burn eschar, the non-viable tissue remaining after burn injury and normally removed to prevent infection, can be a source of mesenchymal cells that may be used for tissue engineering.

12 Jul 2012